{"product_id":"novonordisk-bcg-matrix","title":"Novo Nordisk Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNovo Nordisk's BCG Matrix preview shows where its key products sit—but the real clarity comes with the full report. Buy the complete BCG Matrix to see quadrant-by-quadrant placements, data-driven recommendations, and which brands are true Stars or costly Dogs. Get instant access to a polished Word report plus an Excel summary you can present or act on immediately. Purchase now and turn this snapshot into a strategic roadmap for smarter capital and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWegovy (semaglutide) — obesity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRunaway demand and massive media attention, plus robust outcomes from the 2.4 mg weekly Wegovy (US approval 2021), put it at the star quadrant of a fast-growing obesity market projected to exceed $100 billion by 2030. It consumes heavy capex and commercial spend to expand capacity, launches, and access, yet revenue growth and margin expansion are matching the burn. Keep throttle to lock share while competitors scale; if growth normalizes it can convert into a dominant cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOzempic (semaglutide) — T2D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMarket-leading GLP‑1 for T2D, Ozempic (semaglutide) drives massive prescription momentum and strong payer and physician preference; Novo Nordisk reported Ozempic brought in \u0026gt;$10bn in revenue in 2024 and leads category share. Tailwinds from weight-loss and cardiovascular benefits expand indications, but sustained investment in supply, HCP education and label expansion is required. Hold share now and it will generate significant cash for a decade.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRybelsus (oral semaglutide)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFirst-to-market oral GLP‑1 approved in 2019, Rybelsus gives Novo a unique wedge with needle-averse patients and broadens addressable market.\u003c\/p\u003e\n\u003cp\u003eGrowth runway remains long as awareness and access deepen globally, especially across primary care channels and emerging markets.\u003c\/p\u003e\n\u003cp\u003eStill needs push on adherence, real‑world persistence and clearer payer positioning to translate prescriptions into sustained revenue.\u003c\/p\u003e\n\u003cp\u003eWith scale inside Novo’s GLP‑1 franchise, Rybelsus can become a durable profit engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal GLP‑1 leadership (platform + capacity)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal GLP‑1 leadership is defined less by single products and more by an end-to-end engine — manufacturing scale, API security and device innovation that soak capital yet create a durable moat; by 2024 this platform has enabled faster label and geographic rollouts, multiplying the value of each incremental indication.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform moat: scale across API, manufacturing, devices\u003c\/li\u003e\n\u003cli\u003eCapital intensity: large capex protects share\u003c\/li\u003e\n\u003cli\u003eMultiplicative growth: every new label\/geography leverages same engine\u003c\/li\u003e\n\u003cli\u003eFlywheel: R\u0026amp;D → approvals → scale → reinvestment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardio-metabolic outcomes franchise (label expansions)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompelling outcomes data for GLP-1\/GIP therapies broaden use beyond glucose and weight: STEP trials showed up to 15% mean weight loss, typical HbA1c reductions are 1.0–1.5%, and cardiovascular trials (REWIND, SELECT) demonstrated roughly 12–20% relative MACE risk reductions, each new claim raising the clinical ceiling and strengthening payer value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLabel expansion impact: higher ceiling on eligible population\u003c\/li\u003e\n\u003cli\u003ePayer dynamics: stronger coverage leverage with CV and renal claims\u003c\/li\u003e\n\u003cli\u003eBarriers: promotion and RWE generation remain resource‑intensive\u003c\/li\u003e\n\u003cli\u003eUpside: nailing access compounds category leadership\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP‑1 surge: obesity market \u003cstrong\u003e\u0026gt;$100bn\u003c\/strong\u003e 2030; Ozempic \u003cstrong\u003e\u0026gt;$10bn\u003c\/strong\u003e 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovo’s GLP‑1s sit as Stars: Wegovy\/Ozempic drove runaway demand (obesity market \u0026gt;$100bn by 2030) and Ozempic exceeded $10bn revenue in 2024, funding capex for scale and launches while margins expand. Rybelsus widens the base for needle-averse patients; platform scale (API, manufacturing, devices) multiplies returns but requires heavy spend to defend share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOzempic\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10bn\u003c\/td\u003e\n\u003ctd\u003eMarket leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWegovy\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eHigh demand, obesity upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRybelsus\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eOral wedge\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Novo Nordisk products, showing Stars, Cash Cows, Question Marks, Dogs and strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Novo Nordisk BCG Matrix locating units by growth\/share to surface pain points and guide quick strategy fixes\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin analogs (Tresiba, NovoRapid\/Novolog, Fiasp)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsulin analogs (Tresiba, NovoRapid\/Novolog, Fiasp) are a mature category for Novo Nordisk with a dominant market presence and reliable volumes in 2024. Pricing pressure is real, but global scale and manufacturing efficiency keep margins healthy. Low promotional needs and steady cash conversion make them dependable cash cows. Continue milking while optimizing product mix and production footprint.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVictoza (liraglutide) — legacy GLP‑1\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVictoza (liraglutide) remains a cash cow for Novo Nordisk in 2024, still generating multi-billion DKK annual sales and delivering steady margins despite patent tail effects in several markets. Low growth and limited incremental investment characterize its positioning, making profitability predictable and cash flow harvestable. It functions as a bridge product where newer GLP-1s lack access or reimbursement, so Novo should manage decline gracefully and maximize free cash extraction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorditropin — growth hormone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNorditropin is an established growth-hormone brand within Novo Nordisk with high market share in pediatric and adult GH therapy, driven by repeat patients and predictable demand.\u003c\/p\u003e\n\u003cp\u003eStreamlined distribution and limited promotional needs keep margins stable in a low-growth category, making it a dependable cash generator for the group.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovoSeven — haemostasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNovoSeven — haemostasis remains an entrenched, specialist hospital therapy with strong clinician trust following FDA approval in 1999; switching is cautious so volumes are steady and growth is low but predictable.\u003c\/p\u003e\n\u003cp\u003eOperational efficiency and supply-chain focus outweigh broad marketing spend, making NovoSeven a reliable, high-margin contributor to Novo Nordisk’s specialty portfolio year after year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProduct: NovoSeven (recombinant activated factor VII)\u003c\/li\u003e\n\u003cli\u003eRegulatory milestone: FDA approval 1999\u003c\/li\u003e\n\u003cli\u003eMarket dynamics: specialist hospital use, low churn\u003c\/li\u003e\n\u003cli\u003eCommercial focus: operations \u0026gt; mass marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSaxenda (liraglutide 3mg) — obesity legacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSaxenda (liraglutide 3mg) remains a cash cow in 2024 as legacy obesity revenue persists in markets where GLP‑1 uptake is slower versus semaglutide, though global demand has shifted markedly toward sema. Investments are light because manufacturing and sales infrastructure are already in place. Focus on optimizing pricing, tending existing accounts, and harvesting while promotional resources are redirected to sema.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003etag: legacy revenue — sustained in slower‑uptake markets (2024)\u003c\/li\u003e\n\u003cli\u003etag: low capex — infrastructure established\u003c\/li\u003e\n\u003cli\u003etag: pricing focus — optimize margins\u003c\/li\u003e\n\u003cli\u003etag: promo shift — redirect spend to semaglutide\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHarvest mature franchises; reallocate promo \u0026amp; capex to semaglutide growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInsulin analogs, Victoza, Norditropin, NovoSeven and Saxenda are mature, high-share franchises in 2024 generating steady, high-margin cash flows with low growth and limited incremental investment; prioritize harvest, optimize mix and reallocate promo\/capex to semaglutide opportunities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Sales DKKbn (range)\u003c\/th\u003e\n\u003cth\u003eGrowth %\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin analogs\u003c\/td\u003e\n\u003ctd\u003e20–40\u003c\/td\u003e\n\u003ctd\u003e≈0–3\u003c\/td\u003e\n\u003ctd\u003eCore cash cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVictoza\u003c\/td\u003e\n\u003ctd\u003e~10–15\u003c\/td\u003e\n\u003ctd\u003e−5–0\u003c\/td\u003e\n\u003ctd\u003eHarvest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorditropin\u003c\/td\u003e\n\u003ctd\u003e1–3\u003c\/td\u003e\n\u003ctd\u003e0–2\u003c\/td\u003e\n\u003ctd\u003eStable specialty cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovoSeven\u003c\/td\u003e\n\u003ctd\u003e1–2\u003c\/td\u003e\n\u003ctd\u003e0–1\u003c\/td\u003e\n\u003ctd\u003eHigh-margin specialist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaxenda\u003c\/td\u003e\n\u003ctd\u003e2–4\u003c\/td\u003e\n\u003ctd\u003e−5–5\u003c\/td\u003e\n\u003ctd\u003eLegacy obesity cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eNovo Nordisk BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, just the finished, fully formatted document. It’s crafted for strategic clarity and market-backed insight, ready to download the moment you buy. Use it for presentations, planning, or client work without edits. Nothing in the preview is different from the delivered file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman insulin vials\/mixes (legacy)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuman insulin vials\/mixes (legacy) sit in a low‑growth, commoditized segment with sustained price pressure from generics and tendering; market growth is mid to low single digits. Share is fragmented with limited differentiation, and Novo Nordisk’s overall diabetes franchise held roughly 50% of global insulin revenue in 2024, but legacy vial margins are thin. These products are necessary for access programs, yet capital return is low, so maintain minimal footprint and avoid heavy turnarounds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepaglinide\/older orals (off‑patent)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepaglinide and other off‑patent oral agents show steep generic erosion and no clinical advantage versus newer GLP‑1s, leaving demand muted; in 2024 these legacy orals accounted for under 1% of Novo Nordisk’s diabetes portfolio. Heavy promotion is unlikely to be cost‑effective and the line is cash‑neutral at best, a management attention sink at worst. Clear candidates for pruning or divestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlucaGen HypoKit (legacy glucagon)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlucaGen HypoKit occupies a niche emergency-use segment for severe hypoglycemia, representing under 5% of the broader diabetes acute-care market and generating roughly €50–100m in annual sales in 2024 with modest ~3% CAGR. Intense convenience competition from nasal and ready-to-use glucagon alternatives has capped uptake and margin expansion. Hard to justify large capex given limited upside; maintain minimal spend while keeping supply reliable for strategic coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued\/retired insulin SKUs (e.g., Levemir in select markets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDiscontinued\/retired insulin SKUs like Levemir in select markets are operational drag with little strategic value where withdrawn; transition and regulatory costs often outweigh ongoing benefits, so an orderly wind‑down frees manufacturing, regulatory and commercial resources for growth categories.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOrderly wind‑down\u003c\/li\u003e\n\u003cli\u003eTransition costs \u0026gt; benefits\u003c\/li\u003e\n\u003cli\u003eRedeploy resources to growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommodity pen needles\/accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommodity pen needles\/accessories sit in a highly competitive, price-led segment with low differentiation; the global pen-needle market was about USD 1.1bn in 2024 with single-digit CAGR, so volume without margin adds little to Novo Nordisk’s profitability. Expensive turnarounds and capex to differentiate rarely stick in this low-margin category. Recommend keep operations lean or pursue partnerships\/outsourcing rather than build scale in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2024: ~USD 1.1bn\u003c\/li\u003e\n\u003cli\u003eGrowth: single-digit CAGR\u003c\/li\u003e\n\u003cli\u003eStrategy: lean operations or partner out\u003c\/li\u003e\n\u003cli\u003eRisk: low margins, price-led competition\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrune low-growth insulin vials and orals; keep supply, partner on needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs are low‑growth, low‑share legacy insulin vials, off‑patent orals and accessories that tie up resources with thin margins; Novo Nordisk held roughly 50% of global insulin revenue in 2024 but legacy vial margins are weak. Legacy orals were \u0026lt;1% of the diabetes portfolio in 2024 and GlucaGen HypoKit made ~€50–100m. Strategy: minimal footprint, prune or divest, keep supply for access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eStrategy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy insulin vials\u003c\/td\u003e\n\u003ctd\u003eWithin NN's 50% insulin rev (2024)\u003c\/td\u003e\n\u003ctd\u003emid‑low SD\u003c\/td\u003e\n\u003ctd\u003eMaintain minimal footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy orals\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1% portfolio\u003c\/td\u003e\n\u003ctd\u003edeclining\u003c\/td\u003e\n\u003ctd\u003ePrune\/divest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlucaGen\u003c\/td\u003e\n\u003ctd\u003e€50–100m\u003c\/td\u003e\n\u003ctd\u003e~3% CAGR\u003c\/td\u003e\n\u003ctd\u003eMaintain supply only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePen needles\u003c\/td\u003e\n\u003ctd\u003eMarket ≈USD1.1bn\u003c\/td\u003e\n\u003ctd\u003esingle‑digit\u003c\/td\u003e\n\u003ctd\u003eLean ops\/partner\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCagriSema (cagrilintide + semaglutide) combo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCagriSema (cagrilintide + semaglutide) shows compelling efficacy signals but has zero commercial share today as it remains in development; global obesity drug TAM is projected to exceed USD 100 billion by 2030. Launch execution, payer access, and manufacturing\/supply scale will determine uptake. Novo must commit heavy upfront investment in trials, launch and distribution; if it scales, it can become a Star rapidly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmycretin and next‑gen incretin pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmycretin and next‑gen incretin show high promise across weight and metabolic endpoints but remain early in the curve (Phase 1\/2), needing robust clinical proof, scalable manufacturing plans and payer narratives. Development is cash hungry with uncertain timelines; benchmarking to tirzepatide's SURMOUNT‑1 22.5% mean weight loss highlights big upside if differentiation and phase‑3 data land.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce‑weekly insulin icodec (new markets\/labels)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOnce-weekly insulin icodec, supported by the ONWARDS phase 3 program enrolling \u0026gt;6,000 patients, offers a 7-fold reduction in injection frequency and could materially reset the basal market if clinical outcomes and adherence translate to real-world benefits. Early uptake will likely be choppy as HCPs and payers revise protocols and formularies. Broad adoption requires targeted education, published outcomes and robust device integration. Novo must capture rapid share or face stalled momentum.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardio-renal indications for semaglutide expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCardio-renal expansion targets large adjacent populations (diabetes ~537 million globally; CKD ~850 million affected), but Novo Nordisk’s semaglutide share in these indications remains nascent. Robust trial evidence shows cardiometabolic and renal benefit, yet label wins must convert to prescribing habits and reimbursement to drive uptake; targeted investment can tip standard of care.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge populations: T2D 537m; CKD ~850m\u003c\/li\u003e\n\u003cli\u003eCurrent share: nascent in cardio-renal\u003c\/li\u003e\n\u003cli\u003eBarrier: label→prescribing→reimbursement\u003c\/li\u003e\n\u003cli\u003eEvidence: strong but adoption needs push\u003c\/li\u003e\n\u003cli\u003eRecommendation: invest to tip SOC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease biologics pipeline (e.g., haemophilia innovations)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRare disease biologics for haemophilia offer strong pricing power—eg Hemgenix launched at about 3.5 million USD—targeting small but growing niches; low initial share and complex, high-cost launches raise commercial and clinical risk. Scientific readouts and payer access milestones materially drive valuation; double down where clear differentiation exists and exit where it does not.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh price: Hemgenix ~3.5M USD (launch)\u003c\/li\u003e\n\u003cli\u003eSmall patient pools → high ASP, limited volume\u003c\/li\u003e\n\u003cli\u003eMilestones (efficacy, durability, reimbursement) = value inflection\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObesity TAM \u003cstrong\u003e\u0026gt;USD100B\u003c\/strong\u003e by 2030; T2D \u003cstrong\u003e537M\u003c\/strong\u003e, CKD \u003cstrong\u003e850M\u003c\/strong\u003e — uptake hinges on phase‑3 \u0026amp; pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: mid\/late‑stage obesity\/incretin assets (cagriSema, amycretins), once‑weekly insulin icodec, cardio‑renal and rare biologics show high upside but near‑zero commercial share; 2024 TAM signals: obesity \u0026gt;USD100B by 2030, T2D 537M, CKD ~850M, ONWARDS \u0026gt;6,000 patients; uptake hinges on phase‑3, pricing, reimbursement and manufacturing scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ecagriSema\/amycretins\u003c\/td\u003e\n\u003ctd\u003ePhase2\/3\u003c\/td\u003e\n\u003ctd\u003eObesity TAM \u0026gt;USD100B by 2030\u003c\/td\u003e\n\u003ctd\u003elaunch\/payer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eicodec\u003c\/td\u003e\n\u003ctd\u003ePhase3 ONWARDS\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6,000 enrolled\u003c\/td\u003e\n\u003ctd\u003ereal‑world adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecardio‑renal\u003c\/td\u003e\n\u003ctd\u003eearly uptake\u003c\/td\u003e\n\u003ctd\u003eT2D 537M; CKD ~850M\u003c\/td\u003e\n\u003ctd\u003elabel→reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehaemophilia biologics\u003c\/td\u003e\n\u003ctd\u003elaunch\/early\u003c\/td\u003e\n\u003ctd\u003eASP ~USD3.5M (Hemgenix)\u003c\/td\u003e\n\u003ctd\u003epayer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098303435100,"sku":"novonordisk-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/novonordisk-bcg-matrix.png?v=1781802268","url":"https:\/\/pestel-analysis.com\/products\/novonordisk-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}